Oct. 24, 2025: State Advocacy Update

| 1 Min Read
Contents
  1. New issue brief provides kratom and tianeptine basics, AMA recommendations
  2. More articles in this issue

New issue brief provides kratom and tianeptine basics, AMA recommendations

A new issue brief (PDF) from the AMA Advocacy Resource Center provides key information about kratom and tianeptine—two unregulated substances that have generated increasing reports of public health harms. The issue brief includes basic information about the substances, including the fact that neither has been approved by the U.S. Food and Drug Administration.

Haven't subscribed?

Stay current on the latest on the issues impacting physicians, patients and the health care environment with the AMA’s Advocacy Update newsletter.

Sign Up/Create Account

The AMA recommends the safety and efficacy of kratom should be determined through research and clinical trials and subsequently evaluated by the relevant regulatory entities for its appropriateness for sale and potential oversight via the Controlled Substances Act, before it can be marketed, purchased or prescribed. The AMA also advocates to ban the sale of tianeptine directly to the public in the absence of research into the safety and efficacy of the substance. 

Your Powerful Ally

The AMA is your powerful ally, focused on addressing the issues important to you, so you can focus on what matters most—patients. We will meet this challenge together.

Join Us

FEATURED STORIES

Group of health care workers walk down a hallway

Physician burnout rate continues to decline, falling to nearly 42%

| 5 Min Read
Two health care workers in a hallway

These 9 physician specialties report highest burnout rates

| 7 Min Read
Oversized eyeball wearing a stethoscope

Who should perform intricate surgeries on or around the eye?

| 3 Min Read
Thomas Holland, MD, MS, featured on "Health vs. Hype" AMA podcast

7 things patients should know about protein maxxing

| 5 Min Read